TSFVIT05:	Subjects With On-treatment Clinically Important Vital Signs [Over Time]; Safety Analysis Set (Study jjcs - core)				
Study Visit 	Active Study Agent 	Active Study Agent 	 	
  Parameter 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	
   Criteria, n (%) 	N=53 	N=73 	N=59 	
On-treatment 	 	 	 	
Pulse rate (beats/min) 	 	 	 	
N 	53 	71 	58 	
<50 bpm and with >20 bpm decrease from baseline 	0 	1 (1.4%) 	0 	
>120 bpm and with >30 bpm increase from baseline 	0 	0 	0 	
 	 	 	 	
Systolic blood pressure (mmHg) 	 	 	 	
N 	53 	71 	58 	
<90 mmHg and with >30 mmHg decrease from baseline 	0 	0 	1 (1.7%) 	
>180 mmHg and with >40 mmHg increase from baseline 	0 	0 	1 (1.7%) 	
 	 	 	 	
Diastolic blood pressure (mmHg) 	 	 	 	
N 	53 	71 	58 	
<50 mmHg and with >20 mmHg decrease from baseline 	0 	0 	0 	
>105 mmHg and with >30 mmHg increase from baseline 	0 	0 	0 	
 	 	 	 	
Cycle 02 	 	 	 	
Pulse rate (beats/min) 	 	 	 	
N 	53 	71 	58 	
<50 bpm and with >20 bpm decrease from baseline 	0 	0 	0 	
>120 bpm and with >30 bpm increase from baseline 	0 	0 	0 	
 	 	 	 	
Systolic blood pressure (mmHg) 	 	 	 	
N 	53 	71 	58 	
<90 mmHg and with >30 mmHg decrease from baseline 	0 	0 	0 	
>180 mmHg and with >40 mmHg increase from baseline 	0 	0 	0 	
 	 	 	 	
Diastolic blood pressure (mmHg) 	 	 	 	
N 	53 	71 	58 	
<50 mmHg and with >20 mmHg decrease from baseline 	0 	0 	0 	
>105 mmHg and with >30 mmHg increase from baseline 	0 	0 	0 	
 	 	 	 	
Cycle 04 	 	 	 	
Pulse rate (beats/min) 	 	 	 	
N 	51 	47 	51 	
<50 bpm and with >20 bpm decrease from baseline 	0 	0 	0 	
>120 bpm and with >30 bpm increase from baseline 	0 	0 	0 	
 	 	 	 	
Systolic blood pressure (mmHg) 	 	 	 	
N 	51 	47 	51 	
<90 mmHg and with >30 mmHg decrease from baseline 	0 	0 	0 	
>180 mmHg and with >40 mmHg increase from baseline 	0 	0 	0 	
 	 	 	 	
Diastolic blood pressure (mmHg) 	 	 	 	
N 	51 	47 	51 	
<50 mmHg and with >20 mmHg decrease from baseline 	0 	0 	0 	
>105 mmHg and with >30 mmHg increase from baseline 	0 	0 	0 	

Note: Clinically important vital signs are defined in the Statistical Analysis Plan. N is the number of subjects with at least 1 postbaseline value for the specified vital sign parameter. 	
Note: Clinically important vital signs are defined in the Statistical Analysis Plan. N is the number of subjects with at least 1 postbaseline value for the specified vital sign parameter.	
Note: Clinically important vital signs are defined in the Statistical Analysis Plan. N is the number of subjects with at least 1 postbaseline value for the specified vital sign parameter.	
Note: Clinically important vital signs are defined in the Statistical Analysis Plan. N is the number of subjects with at least 1 postbaseline value for the specified vital sign parameter.	
Note: On-treatment is defined as values obtained after the first dose and within [30 days] following treatment discontinuation. [Only treatment-emergent values (those that worsened from baseline) are presented.] 	: On-treatment is defined as values obtained after the first dose and within [30 days] following treatment discontinuation. [Only treatment-emergent values (those that worsened from baseline) are presented.]	: On-treatment is defined as values obtained after the first dose and within [30 days] following treatment discontinuation. [Only treatment-emergent values (those that worsened from baseline) are presented.]	: On-treatment is defined as values obtained after the first dose and within [30 days] following treatment discontinuation. [Only treatment-emergent values (those that worsened from baseline) are presented.]